SCHEMBL6782227

SCHEMBL6782227

COc1cc(C=O)c(-c2cc(C)ccc2OC)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
AOX1 Q06278 1/20 0.47
ERN1 O75460 9/20 0.46
TDP1 Q9NUW8 2/20 0.44
TRIM24 O15164 2/20 0.44
TRIM33 Q9UPN9 2/20 0.44
HPGD P15428 2/20 0.44
ALDH5A1 P51649 1/20 0.44
ABAT P80404 1/20 0.44
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.42
ACHE P22303 1/20 0.41
TYR P14679 1/20 0.41
TLR2 O60603 1/20 0.41
TLR1 Q15399 1/20 0.41
TLR6 Q9Y2C9 1/20 0.41
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6781018 0.85 ERN1 (0.55) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6777394 0.84 ERN1 (0.61) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6781489 0.84 ERN1 (0.61) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6782462 0.82 ERN1 (0.58) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6782510 0.82 TYR (0.51) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6782947 0.79 ERN1 (0.49) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6785114 0.77 ERN1 (0.60) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6536370 0.76 ERN1 (0.51) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL6779446 0.76 ERN1 (0.54) ALDH1A1AOX1ERN1TDP1TRIM24
SCHEMBL7911724 0.76 GABRA1 (0.54) ALDH1A1TDP1HPGDKDM4EACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825208-B2 SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-11-30 US disclosed
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents TFPI, TFPI2, SERPINC1 ALDH1A1 2602/4885AOX1 1179/4885ERN1 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.